Goldman Sachs
ENVB icon

Goldman Sachs’s Enveric Biosciences ENVB Stock Holding History

Goldman Sachs’s Portfolio ENVB Stock Details ENVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-7
Closed -$55K – 6644
2021
Q4 		$55K Buy
+7
New +$98.4K ﹤0.01% 6246
2019
Q3 		– Hold
0
– -$4K – 5217
2019
Q2 		– Hold
0
– – – 5092
2018
Q4 		– Hold
0
– -$46K – 5341
2018
Q3 		– Hold
0
– – – 5304

Other funds holding ENVB

Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 57.61% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs's ENVB Position: Q1 2022 in Review

Goldman Sachs sold out of Enveric Biosciences (ENVB) in Q1 2022, closing a stake of 7 shares — an estimated $55K sold.

Goldman Sachs first reported a position in ENVB in Q4 2021 and held it in 1 quarter. The position peaked at $55K in Q4 2021. 26 funds tracked by Wall St. Rank hold ENVB as of Q1 2022.

  • Goldman Sachs reported no remaining Enveric Biosciences position as of Q1 2022 after selling out during the quarter.
  • Goldman Sachs sold 7 Enveric Biosciences shares in Q1 2022, an estimated $55K.
  • Goldman Sachs first reported a position in Enveric Biosciences in Q4 2021 and held it in 1 quarter.
  • Goldman Sachs's Enveric Biosciences position peaked at $55K in Q4 2021.
  • 26 funds tracked by Wall St. Rank held Enveric Biosciences as of Q1 2022.

Based on Goldman Sachs's 13F filing for Q1 2022, filed 16 May 2022.